Universidade Federal do Rio de Janeiro | Projeto Praca Onze Pesquisa em Saude

Research site

(Unclaimed)

Location

Avenida Erasmo Braga 255 Salas 203/204/1104, Rio de Janeiro, Rio de Janeiro, Brazil

Site insights

Top conditions

Top treatments

LY3009104

Baricitinib

Nitazoxanide

Xilytol

Survodutide

Cyclosporine

Rosuvastatin

Melissa

Methylprednisolone

Dolutegravir

Parent organization

This site is a part of Universidade Federal do Rio de Janeiro

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

5 of 33 total trials

A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes)

The main purpose of the SYNERGY-OUTCOMES study is to find out whether retatrutide and tirzepatide can prevent major adverse liver outcomes (MALO) in...

Enrolling

Metabolic Dysfunction-Associated Steatotic Liver Disease

Drug: Tirzepatide

Drug: Placebo

A Study of Baricitinib (LY3009104) for the Delay of Stage 3 Type 1 Diabetes in At-Risk Children and Adults (BARICADE-DELAY)

The purpose of this study is to find out if baricitinib can delay the onset of clinical type 1 diabetes (T1D) in people who are at high risk to devel...

Begins enrollment in 1 month

Diabetes Mellitus, Type 1

Drug: Baricitinib

Drug: Placebo

A Study of Baricitinib (LY3009104) to Preserve Beta Cell Function in Children and Adults Newly Diagnosed With Type 1 Diabetes (BARICADE-PRESERVE)

The purpose of this study is to find out if baricitinib can preserve beta-cell function in participants newly diagnosed with type 1 diabetes. Partici...

Begins enrollment in 3 months

Diabetes Mellitus, Type 1

Drug: Baricitinib

Drug: Placebo

A Study of Vedolizumab With and Without Upadacitinib in Adults With Crohn's Disease (VICTRIVA)

The main aim of this study is to learn whether vedolizumab and upadacitinib given together (also called dual targeted therapy or DTT) reduces bowel i...

Enrolling

Crohn's Disease

Drug: Vedolizumab

Drug: Placebo

Locations recently updated

LIVERAGE™: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Moderate or Advanced Liver Fibrosis

This study is open to adults who are at least 18 years old living with obesity and have:* a confirmed liver disease called non-alcoholic steatohepati...

Enrolling

Metabolic Dysfunction Associated Steatohepatitis (MASH)

Liver Fibrosis

Drug: Survodutide

Drug: Placebo